You are here

  • Home
  • Archive
  • Volume 9, Issue 12
  • Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

Citation Tools

Article menu
Letter
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Ortiz-Maldonado V, Rives S, Español-Rego M, et al
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
Journal for ImmunoTherapy of Cancer 2021;9:e003644. doi: 10.1136/jitc-2021-003644